SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

NCT05293912 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Adjustment of clinical development plan

Conditions

Hematological Malignancy
Lymphoma

Interventions

DRUG: SG2501

Sponsor

Hangzhou Sumgen Biotech Co., Ltd.